Abstract

Previous studies of rats with bilateral vestibular deafferentation (BVD) have demonstrated spatial memory deficits, suggesting adverse effects on the hippocampus. However, the longest post-operative time interval that has been studied was approx. 5–7months post-surgery. In this study, we investigated whether rats exhibited spatial memory deficits at 14months following BVD and whether these deficits could be exacerbated by administration of cannabinoid (CB) drugs. Twenty-eight adult rats were divided into four groups: (1) sham surgery+vehicle; (2) sham surgery+the CB1/CB2 receptor agonist WIN55,212-2 (‘WIN’); (3) BVD+vehicle; and (4) BVD+WIN. WIN (1.0 or 2.0mg/kg/day) or vehicle, was administered (s.c.) on days 1–10 and 11–20 (respectively), 30min before the rats performed in a foraging task. On day 21, the CB receptor inverse agonist, AM251 (3.0mg/kg, s.c.), was administered before WIN or vehicle. To our surprise, BVD animals were impaired in using the visual cues during the probe test in light. In the dark trials, when visual cues were unavailable, BVD animals were unable to use self-movement cues in homing. However, WIN at 2mg/kg, significantly improved BVD animals’ homing time and number of errors in the dark through strategies other than the improvement in using self-movement cues. Furthermore, AM251 significantly improved heading angle in vehicle-treated animals and the first home choice in WIN-treated animals. These results suggest that at 14months post-BVD, the animals are not only impaired in path integration, but also piloting and that the spatial memory deficits may be permanent. The involvement of the cannabinoid system is more complicated than expected.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call